0001209191-22-011841.txt : 20220222 0001209191-22-011841.hdr.sgml : 20220222 20220222174406 ACCESSION NUMBER: 0001209191-22-011841 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220218 FILED AS OF DATE: 20220222 DATE AS OF CHANGE: 20220222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smith Brendan CENTRAL INDEX KEY: 0001857492 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 22659638 MAIL ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-18 0 0001674416 CRISPR Therapeutics AG CRSP 0001857492 Smith Brendan C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Financial Officer Stock Option (Right to Buy) 58.29 2022-02-18 4 A 0 30000 0.00 A 2032-02-18 Common Shares 30000 30000 D Restricted Stock Units 2022-02-18 4 A 0 15300 0.00 A Common Shares 15300 15300 D This option was granted on February 18, 2022 with respect to 30,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of March 18, 2022. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. /s/ Michael Esposito, attorney-in-fact 2022-02-22